Catalog No.
RHB90804
Species reactivity
Human
Host species
Mouse
Isotype
IgG1
Clonality
Monoclonal
Applications
ELISA, FCM, IHC
Recommended Dilution
| Application |
Dilution |
| ELISA |
1:10000, FCM: 1:200-1:400, IHC: 1:200-1:1000 |
Target
Proto-oncogene c-Myc, BHLHE39, MYC, Myc proto-oncogene protein, bHLHe39, Transcription factor p64, Class E basic helix-loop-helix protein 39
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01106
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% Sodium Azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
R2X12
Note
For research use only.
[The effect of c-Myc on regulating the immune-related ligands in Y subtype small cell lung cancer through histone deacetylase 1]., PMID:39622733
Prognostic Significance of C-MYC and EGFR Overexpression in Gastrointestinal Stromal Tumors: An Immunohistochemical Study., PMID:39636317
Extrajunctional CLDN10 cooperates with LAT1 and accelerates clear cell renal cell carcinoma progression., PMID:39639312
Nanotechnology-Enabled Targeted Protein Degradation for Cancer Therapeutics., PMID:39663650
Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma., PMID:39672382
The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer., PMID:39679910
ITGA3 promotes pancreatic cancer progression through HIF1α- and c-Myc-driven glycolysis in a collagen I-dependent autocrine manner., PMID:39690180
Potassium/sodium cation carriers robustly up-regulate CD20 antigen by targeting MYC, and synergize with anti-CD20 immunotherapies to eliminate malignant B cells., PMID:39704178
Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic Leukemia., PMID:39716442
AptaFluorescence: An aptamer-based fluorescent imaging protocol for biomolecule visualization., PMID:39729513
Antisense oligonucleotides-based approaches for the treatment of multiple myeloma., PMID:39732226
[Clinical Features and Prognosis of Patients with Primary Extranodal Diffuse Large B-Cell Lymphoma]., PMID:39743255
Zanubrutinib plus R-CHOP for the treatment of newly diagnosed double-expressor lymphoma: A phase 2 clinical study., PMID:39748728
Depletion of myeloid-derived suppressor cells sensitizes murine multiple myeloma to PD-1 checkpoint inhibitors., PMID:39755583
Targeted Next-Generation Sequencing of Cell-Free DNA to Detect MYC-Immunoglobulin Translocation and Epstein-Barr Virus DNA in Plasma of Burkitt Lymphoma Patients in East Africa., PMID:39787450
Impacts of genomic alterations on the efficacy of HER2-targeted antibody-drug conjugates in patients with metastatic breast cancer., PMID:39806366
Investigation of circulating natural autoantibodies against ANXA1 and MYC as potential biomarkers in hepatocellular carcinoma., PMID:39824386
Subtype-specific human endogenous retrovirus K102 envelope protein is a novel serum immunosuppressive biomarker of cancer., PMID:39850893
Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets., PMID:39855192
PSMA antibody, humanized PSMA.CAR10.3, or Cetuximab increases prostate cancer localization of NF-κB p50-deficient immature myeloid cells (p50-IMC) and phagocytosis by their macrophage progeny., PMID:39904797
Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence., PMID:39914385
Phase 1 trial of durvalumab (anti-PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma., PMID:39951620
A dual-mode immunosensor for detection of oncoprotein c-Myc via indirect competition using trimetallic nanocomposite as an excellent label., PMID:39984205
Nanoparticle-Mediated Toll-Like Receptor Activation and Dual Immune Checkpoint Downregulation for Potent Cancer Immunotherapy., PMID:40009747
Sialylated IgG-activated integrin β4-Src-Erk axis stabilizes c-Myc in a p300 lysine acetyltransferase-dependent manner to promote colorectal cancer liver metastasis., PMID:40010102
Blood-brain barrier crossing biopolymer targeting c-Myc and anti-PD-1 activate primary brain lymphoma immunity: Artificial intelligence analysis., PMID:40088978
Diffuse large B-cell lymphoma with partial low Ki67 proliferation index., PMID:40138154
Zanubrutinib plus R-CHOP improves the treatment effect of newly diagnosed diffuse large B cell lymphoma with double expression of MYC and BCL-2., PMID:40145086
Current and future therapies for small cell lung carcinoma., PMID:40170056
Synergistic activity of tafasitamab and metronomic chemotherapy on diffuse large B-cell lymphoma through inhibition of the AKT/mTOR signaling pathway., PMID:40175588
Establishment of a novel human basophil cell line for functional analysis and in vitro allergy testing., PMID:40187962
Multimerized epitope tags for high-sensitivity protein detection., PMID:40191928
Ultrasound-guided percutaneous radiofrequency ablation combined with anti-PD-1 for the treatment of prostate cancer: an experimental study., PMID:40196732
ID3 enhances PD-L1 expression by restructuring MYC to promote colorectal cancer immune evasion., PMID:40208940
Successful treatment of primary refractory DLBCL/HGBL - MYC/BCL2 transformed from FL using glofitamab: a case report., PMID:40230856
Multiplexed imaging mass cytometry elicits p-S6 as a therapeutic and prognostic factor in diffuse large B-cell lymphoma., PMID:40238894
The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse., PMID:40241199
ZMYND8 drives HER2 antibody resistance in breast cancer via lipid control of IL-27., PMID:40281007
Astrocyte Elevated Gene-1/Metadherin (AEG-1/MTDH): A Promising Molecular Marker and Therapeutic Target for Hepatocellular Carcinoma., PMID:40282551
The protein deacetylase HDAC10 controls DNA replication in malignant lymphoid cells., PMID:40301616
Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer., PMID:40346041
Inhibition of Purine Metabolism Promotes the Differentiation of Neuroblastoma Driven by MYCN., PMID:40353332
Hepatocyte-specific C-C motif chemokine ligand 9 signaling promotes liver fibrosis progression in mice., PMID:40359088
Deciphering the history of ERK activity from fixed-cell immunofluorescence measurements., PMID:40399273
B cell receptor silencing reveals origin and dependencies of high-grade B cell lymphomas with MYC and BCL2 rearrangements., PMID:40402557
Engineered E. coli OMVs Carrying the Membrane-Binding hGC33 Fragment Precisely Target Liver Cancer and Effectively Treat Tumor., PMID:40433120
B-cell lymphoma: Advances in pathogenesis, diagnosis, and targeted therapies., PMID:40435909
Prognostic Value of the G2 Expression Signature and MYC Overexpression in Childhood High-Grade Osteosarcoma., PMID:40440582
Nanobody-based fluorescent immunoassay for SARS-CoV-2 spike detection via site-specific microbial transglutaminase labeling., PMID:40483875
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study., PMID:40532125
For research use only. Not for human or drug use.
